Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is N/A as of 2026-10-06T20:38:20.368Z.
Calculation as of: 2026-10-06T20:38:20.368Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ad03cc2eaddb42082332b148aee8d6851fa015397d59a0785f41cacae5aa3ea4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
N/A
Market Cap
$656.59M
PB Ratio
1.61
TTM Avg
1.56
3Y Avg
1.46
5Y Avg
1.68
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Starling Oncology, Inc. (STLN) | $657.89M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | 1.61 | 1.56 | 1.46 | 1.68 |
| Annexon, Inc. (ANNX)vs › | $660.29M | 3.55 | 4.58 | 2.76 | 2.17 |
| Helus Pharma Inc. (HELP)vs › | $666.95M | 2.76 | 1.21 | 1.21 | 1.21 |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 3.12 | 3.17 | 4.99 | 414.87 |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | 2.02 | 2.93 | 2.40 | 2.52 |
| Verastem, Inc. (VSTM)vs › | $681.02M | 13.62 | 10.27 | 9.24 | 6.31 |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | 1.82 | 2.82 | 1.85 | 1.30 |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 2.91 | 3.69 | 5.55 | 4.17 |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | 15.88 | 7.32 | 4.65 | 4.60 |
P/B Ratio
N/A
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
